ReproCELL– tag –
-
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL Spain Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. Th... -
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stemchymal® Stem Cell Therapy for Spinocerebellar Ataxia (SCA3 and SCA6)
BioSpace Japan Overview REPROCELL Inc. has submitted an application for manufacturing and marketing approval in Japan for its regenerative medicine product, Stemchymal®, aimed at inhibiting the progression of motor ataxia in patients wit... -
Streamlining PBMC Processing in Multi-Site Clinical Trials Bridges Translational Gap in Drug Discovery
REPROCELL Blog Japan Overview Efficient processing of peripheral blood mononuclear cells (PBMCs) in multi-site clinical trials is crucial for bridging the translational gap in drug discovery. This article identifies key challenges and pr... -
REPROCELL Standardizes and Streamlines PBMC Processing for Multi-Site Clinical Trials with Semi-Automated, Closed Systems and Fully Automated Microfluidic Platforms
REPROCELL Japan Overview A REPROCELL article addresses challenges in Peripheral Blood Mononuclear Cell (PBMC) processing for multi-site clinical trials by introducing innovative solutions to enhance efficiency and standardization. Improv... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
REPROCELL Unveils AI-Designed CRISPR for Hypoimmune iPSC Engineering, Accelerating Off-the-Shelf Cell Therapy Development
REPROCELL Japan Overview REPROCELL announced that its StemEdit platform, integrating AI-designed CRISPR with optimized workflows, has achieved high gene-editing efficiency and reduced off-target activity in induced pluripotent stem cells...
12